Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Sana Biotechnology Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.62 (market cap $1.45B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: YieldMax NVDA Option Income Strategy ETF is the larger of the two by market cap, and YieldMax NVDA Option Income Strategy ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and Sana Biotechnology Inc for 23 Days on average.
| NVDY | SANA | |
|---|---|---|
Market Cap | $1.45B | $836.71M |
Volume | 1,943,739 | 4,507,444 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $5.92 |
52-Week Low | $11.58 | $2.68 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $12.57, down 3.38% with a bearish technical outlook. The ETF generates weekly dividends but faces structural limitations on upside participation. Recent analyst coverage highlights concerns about declining volatility reducing option income potential. Technical indicators show bearish momentum with support at $12 and resistance at $13.
The outlook remains cautious as NVDY's high distribution yield comes at the cost of NAV erosion. While weekly dividends provide income, the fund's capped upside during NVIDIA rallies and dependence on volatility create long-term performance challenges. Investors seeking pure NVIDIA exposure may find direct ownership more attractive.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
